Status:
COMPLETED
Efficacy of Pathogen Inactivation Strategies for Platelet Transfusion
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Cardiopulmonary Bypass Surgery
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is a prospective randomized clinical trial designed to determine the hemostatic ability of pathogen reduced platelet, when compared to non-pathogen reduced platelets suspended in platelet additiv...
Detailed Description
The safety and efficacy of pathogen reduced (PRT) platelets (PLTs) have been investigated in several controlled clinical studies. Most of these clinical studies evaluated the efficacy of PRT PLTs duri...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Preoperative evaluation for risk of transfusion: platelet count \< 200,000/mcl, OR anticipated time on cardiopulmonary bypass \> 90 min, OR complex cardiac surgery, OR use of preoperative antiplatelet therapy within 3-5 days of surgery.
Exclusion
- Patient that lack the ability to consent
- Patients with the diagnosis of idiopathic thrombocytopenia purpura,
- Patient with the diagnosis of heparin-induced thrombocytopenia.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06535360
Start Date
September 1 2020
End Date
May 31 2023
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201